Conexeu Debuts on Nasdaq With Preclinical Regenerative Tissue Platform

Conexeu Sciences, a regenerative tissue engineering company, has completed its Nasdaq debut to advance its bioregeneration platform technology. The preclinical-stage company aims to develop biological solutions for restoring lost or damaged tissues, potentially opening new applications in construction-related injury recovery and worker health.

Conexeu Sciences, a preclinical-stage regenerative tissue platform company, debuted on Nasdaq, framing the public listing as a milestone for its mission of “Architecting Bioregeneration” and for the development of a platform designed to support the biological conditions needed to restore lost or…

This story was originally published by 3D Printing Industry.